Tag: Tumor
Enhertu shows promising results in DESTINY-PanTumor02 Phase 2 trial
The DESTINY-PanTumor02 Phase II trial revealed high-level results for AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), showcasing clinically meaningful progression-free survival (PFS) and overall survival ... Read More
Thermo Fisher Scientific launches Gibco OncoPro Tumoroid Culture Medium Kit
Fisher Scientific, a global leader in serving science, unveiled its latest product, the Gibco OncoPro Tumoroid Culture Medium Kit to expedite development of novel cancer ... Read More
MEDiC Life Sciences, Bristol Myers Squibb to advance discovery of tumor targets
MEDiC Life Sciences, a biotech startup based in Silicon Valley, has announced a research collaboration with pharmaceutical giant Bristol Myers Squibb to advance the discovery ... Read More
Clinical-stage pharma firms Ayala Pharmaceuticals, Advaxis sign merger deal
Ayala Pharmaceuticals, a Nasdaq-listed clinical-stage oncology company, has entered into a merger deal with New Jersey-based biotech company Advaxis. Based in Delaware, Ayala Pharmaceuticals is ... Read More
Gilead gets Trodelvy FDA priority review for pre-treated HR+/HER2- metastatic breast cancer
Gilead Sciences said that Trodelvy (sacituzumab govitecan-hziy) has been granted priority review from the US Food and Drug Administration (FDA) for the treatment of another ... Read More
Cue Biopharma gets FDA fast track status for CUE-101 in HPV16+ R/M HNSCC
Cue Biopharma has been granted fast track designation for CUE-101 from the US Food and Drug Administration (FDA) for the treatment of a type of ... Read More
Ayala Pharmaceuticals AL102 gets FDA fast track status in desmoid tumors
Ayala Pharmaceuticals has been granted fast track designation for its oral gamma-secretase inhibitor AL102 by the US Food and Drug Administration (FDA) for the treatment ... Read More
BriaCell Therapeutics gets license for anti-cancer agent sCD80 from UMBC
BriaCell Therapeutics has signed an exclusive licensing deal with the University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a ... Read More
HUTCHMED begins HMPL-A83 phase 1 trial in advanced malignant neoplasms
HUTCHMED (China) has launched a phase 1 clinical trial of its oncology drug candidate HMPL-A83 in China in patients having advanced malignant neoplasms. HMPL-A83 is ... Read More
Ipsen to acquire American biopharma company Epizyme for $247m
French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration of $247 million. Epizyme, which is listed ... Read More